Phase III trial in 463 patients with previously treated HER2+ advanced breast cancer: tucatinib plus T-DM1 vs T-DM1 alone improved median PFS (9.5 vs 7.4 months; HR 0.76), but grade ≥3 adverse events were higher (68.8% vs 41.2%).
RCTn = 463
Hurvitz et al. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02